comparemela.com

Latest Breaking News On - Antonio breast cancer symposium - Page 3 : comparemela.com

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides ...

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024

United-states
Jennifer-caswell-jin
Christopherm-calabrese
Kevin-gardner
Steve-worland
Mike-tattory
Christian-curtis
Lifesci-communications
Exchange-commission
Roberth-lurie-comprehensive-cancer-center
Nasdaq
Pfizer

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expect.

United-states
Kevin-gardner
Christian-curtis
Jennifer-caswell-jin
Mike-tattory
Christopherm-calabrese
Steve-worland
University-of-california-san-francisco
Northwestern-university
Nasdaq
Effector-therapeutics-inc
Lifesci-communications

Post-Surgery Atezolizumab Fails to Provide Benefit in Combination With Chemotherapy for TNBC

Adjuvant atezolizumab did not provide a clinical benefit when added to chemotherapy in patients with triple-negative breast cancer.

Italy
Milan
Lombardia
San-antonio
Texas
United-states
Heather-mcarthur
Clinical-breast-cancer-research
Ut-southwestern-medical-center
European-breast-cancer-conference
Komen-distinguished-chair
Medical-center

Olema Oncology Reports Fourth Quarter and Full-Year 2023

Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4.

Massachusetts
United-states
San-francisco
California
Spain
Madrid
Cambridge
Cambridgeshire
United-kingdom
Berlin
Germany
Geoffrey-mogilner

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib.

Germany
Spain
Massachusetts
United-states
Madrid
San-francisco
California
Berlin
Cambridge
Cambridgeshire
United-kingdom
Geoffrey-mogilner

vimarsana © 2020. All Rights Reserved.